Patel Sanjiv 4

What Happened

• Sanjiv Patel, President, CEO and Director of Relay Therapeutics, reported two transactions: he sold 48,199 shares in an open-market sale on 2026-07-07 for weighted average proceeds of $943,736 (weighted avg price $19.58), and he acquired 3,056 shares under the company’s 2020 Employee Stock Purchase Plan (ESPP) on 2026-06-30 for $6.95 per share, totaling $21,239. The sale was effected under a pre-established Rule 10b5-1 trading plan.

Key Details

• Sale date and price: 2026-07-07 — 48,199 shares sold; weighted average price $19.58; price range across trades $18.52–$20.20. (Reporting person can provide breakdown on request.)
• Purchase date and price: 2026-06-30 — 3,056 ESPP shares acquired at $6.95 each (85% of the issuer’s closing price on Jan 2, 2026).
• Plan/authorization: Sale effected pursuant to a Rule 10b5-1 plan adopted Oct 30, 2025; ESPP purchase exempt under Rule 16b-3 and voluntarily reported.
• Trust holdings: Filing notes certain shares are held in irrevocable trusts for family members and the reporting person disclaims beneficial ownership of those shares.
• Shares owned after transaction: Not specified in this Form 4.
• Filing timeliness: Form 4 filed 2026-07-08 for transactions reported through 2026-07-07 (filed the next day).

Context

• The ESPP purchase is a routine employee benefit (discounted purchase) and the purchase price reflects the plan’s 85% pricing. The sale was made under a 10b5-1 plan, indicating it was pre-arranged rather than an ad hoc trade. As always, these disclosures are factual records of insider activity and do not, by themselves, indicate company performance or the insider’s private views.